Welcome to our dedicated page for Nu-Med Plus SEC filings (Ticker: NUMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Nu-Med Plus's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Nu-Med Plus's regulatory disclosures and financial reporting.
Nu-Med Plus, Inc. is a development-stage medical device company focused on nitric oxide delivery systems for hospital, clinical, portable, disposable and research applications. Product development has been suspended until new capital is raised, and the company has not yet submitted any devices for FDA approval.
At December 31, 2025, Nu-Med had total assets of $7,911, including cash of $661, and total liabilities of $279,189, reflecting a highly strained balance sheet. The company generated no revenue in 2025, incurred operating expenses of $48,955 and interest expense of $7,227, resulting in a net loss of $56,182, narrower than the prior year’s $68,345 loss.
Management and the auditor both highlight substantial doubt about Nu-Med’s ability to continue as a going concern. The company estimates it needs $1,250,000 over the next year to execute its plan of operations but currently has no committed financing and expects to rely on loans and equity sales. Internal control over financial reporting is assessed as ineffective due to limited staffing and lack of segregation of duties.
Nu-Med qualifies as an emerging growth company and smaller reporting company and intends to use reduced disclosure and extended accounting standard transition provisions. It holds two approved patents and one pending for its nitric oxide systems, but with only two employees and intense competition from much larger device and pharmaceutical companies, commercialization of any product is described as being years away.
Nu-Med Plus, Inc. notified the SEC it will file its Annual Report on Form 10-K for the period ended December 31, 2025 after the prescribed deadline under Rule 12b-25.
The company states it is completing audited financial statements and expects to file the 10-K on or before April 15, 2026. The company indicates no anticipated significant change in results of operations versus the prior year.
Nu‑Med Plus (NUMD) filed its Q3 2025 10‑Q, reporting no revenue and a net loss of $11,966 for the quarter and $43,564 for the nine months ended September 30, 2025. Operating expenses declined year over year, reflecting lower professional fees.
Liquidity remains tight: cash was $1,948 and total assets $5,048 against current liabilities of $263,708, resulting in a working capital deficiency of $258,660. Management disclosed planned expenditures of approximately $1,200,000 over the next twelve months and stated the company is funded through November 30, 2025, raising substantial doubt about continuing as a going concern.
Product development is suspended until capital infusion. Financing relied on related parties, including a $100,000 note to YSA and August 15, 2025 notes of $12,500 and $87,500 at 5% payable on demand. Disclosure controls and procedures were deemed not effective. Common shares outstanding were 83,548,469 as of November 14, 2025.